Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
maraviroc + PF-03716539
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Maraviroc is a small molecule C-C chemokine receptor type 5 (CCR5) co-receptor antagonist used in combination with other antiretroviral agents for the treatment of CCR5-tropic HIV-1 infection in adults and pediatric patients. It works by allosterically inhibiting the CCR5 chemokine coreceptor, thereby preventing HIV from entering and infecting host cells[1][6][7][8]. Maraviroc is marketed under the brand name Selzentry (Celsentri outside the US) and was developed by Pfizer. PF-03716539 is a code name for an investigational compound that has been evaluated in phase 1 studies for safety, tolerability, and pharmacokinetics in healthy volunteers[4]. The combination "maraviroc + PF-03716539" refers to both drugs being studied or administered together; however, there is no evidence that this specific combination has been approved or widely studied beyond early-phase trials.
- Other names
- CelsentriMVC
02
Targets
CCR5 (C-C chemokine receptor type 5)
Beyond the preview
Go deeper on maraviroc + PF-03716539.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on maraviroc + PF-03716539.